Abstract | BACKGROUND: A unique time in which to effectively treat an intraabdominal malignancy is the time at which the surgeon attempts complete removal of the malignant process. Although surgery is effective for visible disease, micrometastases or multiple small cancer nodules are not amenable to resection. Alternative interventions to deal with residual disease disseminated on peritoneal surfaces are needed. MATERIALS AND METHODS: RESULTS: Patients with high grade serous ovarian cancer underwent CRS, HIPEC with cisplatin/ doxorubicin, and EPIC paclitaxel. These treatments combined as a single intervention were studied in 10 patients. The median number of peritonectomy procedures was 1, the median number of visceral resections was 5, and the median time required in the operating room was 8 h. Two patients had a class 3 adverse event. The median survival of patients was 50 months. Pharmacokinetic analysis of the intraperitoneal paclitaxel showed 252 ± 153 times exposure of peritoneal surfaces as compared to intravenous exposure when the drug was instilled into the peritoneal space. CONCLUSIONS:
|
Authors | Paul H Sugarbaker, O Anthony Stuart |
Journal | Surgical oncology
(Surg Oncol)
Vol. 35
Pg. 441-446
(Dec 2020)
ISSN: 1879-3320 [Electronic] Netherlands |
PMID | 33039850
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Cystadenocarcinoma, Serous
(pathology, therapy)
- Cytoreduction Surgical Procedures
(mortality)
- Doxorubicin
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Hyperthermia, Induced
(mortality)
- Hyperthermic Intraperitoneal Chemotherapy
(mortality)
- Middle Aged
- Ovarian Neoplasms
(pathology, therapy)
- Peritoneal Neoplasms
(secondary, therapy)
- Pilot Projects
- Prognosis
- Survival Rate
- Young Adult
|